menu
    • menu

    Company profile for Alentis Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (esp. hepatocellular carcinoma, HCC). Alentis has in-licensed platform technologies and monoclonal antibodies which are the result of more than a decade of research from University Strasburg / INSERM. The portfolio is based on deep competence in liver diseases and fibrosis and the d...
    Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (esp. hepatocellular carcinoma, HCC). Alentis has in-licensed platform technologies and monoclonal antibodies which are the result of more than a decade of research from University Strasburg / INSERM. The portfolio is based on deep competence in liver diseases and fibrosis and the discovery of a novel, very fundamental mechanism of action underlying these diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alentis TherapeuticsSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Hochbergerstrasse 60C 4057 Basel
    Telephone
    Telephone
    +49 157 5877 9471
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://alentis.ch/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alentis Strengthens Management Team With Key Appointments
    Alentis Strengthens Management Team With Key Appointments

    12 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251112405811/en/Alentis-Strengthens-Management-Team-with-Key-Appointments

    BUSINESSWIRE
    12 Nov 2025
    Share Share
    Alentis Appoints Mark Pruzanski As CEO
    Alentis Appoints Mark Pruzanski As CEO

    15 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-15/alentis-appoints-mark-pruzanski-as-ceo

    PHARMIWEB
    15 Oct 2025
    Share Share
    Catalio bankrolls biotechs with $400M-plus fund
    Catalio bankrolls biotechs with $400M-plus fund

    01 Jul 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/catalios-400m-fund-takes-advantage-historic-buyers-market-biotech

    FIERCE BIOTECH
    01 Jul 2025
    Share Share
    Alentis Positive Results For Lixudebart In ANCA-RPGN & Fibrosis
    Alentis Positive Results For Lixudebart In ANCA-RPGN & Fibrosis

    09 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250109789929/en

    BUSINESSWIRE
    09 Jan 2025
    Share Share
    Alentis Receives FDA Fast Track for ALE.P02 in CLDN1+ Solid Tumors
    Alentis Receives FDA Fast Track for ALE.P02 in CLDN1+ Solid Tumors

    18 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241118754051/en

    BUSINESSWIRE
    18 Nov 2024
    Share Share
    Alentis Therapeutics Raises $181.4M for Anti-Claudin-1 ADCs
    Alentis Therapeutics Raises $181.4M for Anti-Claudin-1 ADCs

    12 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241112618033/en

    BUSINESSWIRE
    12 Nov 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search